Casi Pharmaceuticals (CASI) said Thursday its board received an updated non-binding proposal from Chairman and CEO Wei-Wu He to acquire its entire business operations in China for $20 million.
The proposal includes the acquisition of all of the company's license-in, distribution, and related rights in Asia, excluding Japan, related to certain of its pipeline products. The latest offer updates a preliminary non-binding proposal that He submitted in June 2024, Casi said.
The company's shares were 11.5% higher in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。